一种治疗方法涉及用定制抗体标记B细胞表面上的CD20蛋白。这触发了一系列免疫反应，并最终导致癌细胞的破坏。 这类免疫治疗抗体已经用于治疗 ...

As immature B cells expressing autoreactive antigen receptors are not depleted by anti-CD20 mAb, a new strategy for eliminating autoantigen-selected B cells and for treating early lymphoblastic ...

CD20 Molecule Background B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1 ...

Rituximab is a chimeric mouse–human monoclonal antibody with high specificity and affinity for the CD20 antigen. CD20 is expressed on B lymphocytes from the pre-B stage to the mature B stage ...

Ofatumumab shows good efficacy in conditions with low CD20 expression and is approved for relapsed/refractory chronic lymphocytic leukemia (CLL). Veltuzumab shows low immunogenicity and can be ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

Ofatumumab shows good efficacy in conditions with low CD20 expression and is approved for relapsed/refractory chronic lymphocytic leukemia (CLL). Veltuzumab shows low immunogenicity and can be ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure The newly launched article Structure of ...

Instead of a patient-specific antigen, they needed to find a more generic antigen. When Nadler ran into Levy and Miller at a conference, he recalled suggesting, “You’re going about this all wrong.